Cargando…
Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
BACKGROUND: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult...
Autores principales: | Sirima, Sodiomon B., Tiono, Alfred B., Ouédraogo, Alphonse, Diarra, Amidou, Ouédraogo, André Lin, Yaro, Jean Baptiste, Ouédraogo, Espérance, Gansané, Adama, Bougouma, Edith C., Konaté, Amadou T., Kaboré, Youssouf, Traoré, Abdoulaye, Roma, Chilengi, Soulama, Issiaka, Luty, Adrian J. F., Cousens, Simon, Nébié, Issa |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764341/ https://www.ncbi.nlm.nih.gov/pubmed/19855847 http://dx.doi.org/10.1371/journal.pone.0007549 |
Ejemplares similares
-
Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2010) -
Seasonal performance of a malaria rapid diagnosis test at community health clinics in a malaria-hyperendemic region of Burkina Faso
por: Diarra, Amidou, et al.
Publicado: (2012) -
Clinical Variation of Plasmodium falciparum eba-175, ama-1, and msp-3 Genotypes in Young Children Living in a Seasonally High Malaria Transmission Setting in Burkina Faso
por: Soulama, Issiaka, et al.
Publicado: (2015) -
Variation in haematological parameters in children less
than five years of age with asymptomatic Plasmodium infection:
implication for malaria field studies
por: Gansane, Adama, et al.
Publicado: (2013) -
A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age
por: Ouédraogo, Alphonse, et al.
Publicado: (2013)